MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-08-2022
Albireo Pharma DIO Ratio 2011-2025 | ALBO
Annual DIO Ratio Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 26.1 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 26.1 | 26.1 | 26.1 |
Quarterly DIO Ratio Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 391 | 230 | 393 | - | 20.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 393 | 20.8 | 259 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
42.1 | $ 3.2 | -1.69 % | $ 247 M |  USA |
 |
Aptevo Therapeutics
APVO
|
112 | $ 1.07 | -5.75 % | $ 295 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B | USA |
 |
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - |  Russia |
 |
Acasti Pharma
ACST
|
136 | - | 4.01 % | $ 150 M |  Canada |
 |
Amphastar Pharmaceuticals
AMPH
|
132 | $ 26.45 | 4.67 % | $ 1.28 B | USA |
 |
Anika Therapeutics
ANIK
|
247 | $ 9.6 | 0.37 % | $ 141 M | USA |
 |
Catalyst Biosciences
CBIO
|
410 | $ 12.98 | -7.91 % | $ 854 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
160 | - | -6.81 % | $ 3.04 B | USA |
 |
Axon Enterprise
AXON
|
116 | $ 548.58 | -2.78 % | $ 41.6 B | USA |
 |
Aytu BioScience
AYTU
|
209 | $ 2.37 | 2.83 % | $ 14.9 M | USA |
 |
AstraZeneca PLC
AZN
|
206 | $ 91.59 | 1.95 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
345 | - | -24.86 % | $ 820 K | USA |
 |
BeiGene, Ltd.
BGNE
|
304 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
239 | $ 11.33 | -1.78 % | $ 733 M | USA |
 |
Biogen
BIIB
|
394 | $ 175.2 | 0.63 % | $ 25.5 B | USA |
 |
Abeona Therapeutics
ABEO
|
265 | $ 5.07 | -5.5 % | $ 108 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
338 | $ 87.67 | -0.36 % | $ 9.05 B | USA |
 |
ADiTx Therapeutics
ADTX
|
220 | $ 1.43 | -36.18 % | $ 18.8 K | USA |
 |
Berkeley Lights
BLI
|
246 | - | -7.31 % | $ 87 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
93.3 | $ 24.29 | 2.84 % | $ 2.88 B | USA |